BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37857377)

  • 21. ProNetView-ccRCC: A Web-Based Portal to Interactively Explore Clear Cell Renal Cell Carcinoma Proteogenomics Networks.
    Kalayci S; Petralia F; Wang P; Gümüş ZH
    Proteomics; 2020 Nov; 20(21-22):e2000043. PubMed ID: 32358997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response.
    Bukur J; Malenica B; Huber C; Seliger B
    Hum Immunol; 2003 Nov; 64(11):1081-92. PubMed ID: 14602239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
    Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA
    Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
    Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
    Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma.
    Jiang YZ; Li QH; Zhao JQ; Lv JJ
    Asian Pac J Cancer Prev; 2014; 15(5):2309-12. PubMed ID: 24716975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma.
    Kobayashi S; Tokita S; Moniwa K; Kitahara K; Iuchi H; Matsuo K; Kakizaki H; Kanaseki T; Torigoe T
    JCI Insight; 2023 Aug; 8(16):. PubMed ID: 37606040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure, expression and function of HLA-G in renal cell carcinoma.
    Seliger B; Schlaf G
    Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
    Xu HH; Wang HL; Xing TJ; Wang XQ
    Front Immunol; 2022; 13():851622. PubMed ID: 35924232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
    Seliger B; Dressler SP; Massa C; Recktenwald CV; Altenberend F; Bukur J; Marincola FM; Wang E; Stevanovic S; Lichtenfels R
    Proteomics; 2011 Jun; 11(12):2528-41. PubMed ID: 21595034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases.
    Ferns DM; Heeren AM; Samuels S; Bleeker MCG; de Gruijl TD; Kenter GG; Jordanova ES
    J Immunother Cancer; 2016; 4():78. PubMed ID: 27895918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes.
    Amatschek S; Koenig U; Auer H; Steinlein P; Pacher M; Gruenfelder A; Dekan G; Vogl S; Kubista E; Heider KH; Stratowa C; Schreiber M; Sommergruber W
    Cancer Res; 2004 Feb; 64(3):844-56. PubMed ID: 14871811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients.
    Tronik-Le Roux D; Renard J; Vérine J; Renault V; Tubacher E; LeMaoult J; Rouas-Freiss N; Deleuze JF; Desgrandschamps F; Carosella ED
    Mol Oncol; 2017 Nov; 11(11):1561-1578. PubMed ID: 28815885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
    Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
    Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M; Rosenberg SA
    Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics.
    Qifeng S; Bo C; Xingtao J; Chuanliang P; Xiaogang Z
    J Thorac Cardiovasc Surg; 2011 Mar; 141(3):808-14. PubMed ID: 21335133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
    García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
    BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
    Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
    Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma.
    Kloth JN; Gorter A; Fleuren GJ; Oosting J; Uljee S; ter Haar N; Dreef EJ; Kenter GG; Jordanova ES
    J Pathol; 2008 Jul; 215(3):222-30. PubMed ID: 18438953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.